Abstract 1066
Background
Ostomy patients (pts) can develop some complications treated by nurse enterostomista, such as skin alterations and early or late complications. Stomal complications have a varying incidence (from 25 to 35%). Neoplastic ostomy pts often undergo chemo (CT) and/or radiation therapy (RT), also in association, and they can show stomal lesions or complications with an important impact on their daily life. Stomal side effects induced by CT-RT represent an important problem for pts, who need for a competent and organized support in order to be able to cope with them. In the literature, few studies report the care and assistance to the stomized pts.The aim of this study was to detect precociously stomal complications in order to treat them early, improving pts quality of life, and to demonstrate that these complications are more frequent in pts treated with CT and/or RT.
Methods
From 11.2017 to 5.2018 60 cancer ostomy pts were surgically treated for different types of cancers at our institution. 29 out 60 have been also treated with CT and/or RT at Medical Oncology Dept. 73% were male and 27% female. We evaluated stomal complications and classified them according to SACS scale. Our aim was to demonstrate a higher percentage of stomal complications in pts CT and/or RT treated vs untreated pts.
Results
At a median follow-up of 4 months, 29 out 60 ostomy pts were treated with CT, 2 with CT-RT, the remaining 29 underwent follow-up. 15 out 29 pts (51%) treated with CT and/or RT showed stomal complications: 14 with SACS - L1 skin alterations (redness without loss of substance) and 1 with SACS-L2 lesion (with loss of substance). Patients undergoing follow-up didn’t have any stomal complications.
Conclusions
Despite the recognized limitations of our study (small sample size and short median follow-up) we can conclude that there is an increase of complications in ostomy pts treated with CT and/or RT vs untreated pts and that this problem occurs in over half of population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cristoforo Ferrero.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract